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Background/Aims: Many patients with aspirin-induced asthma have severe methacholine airway hyperre-
sponsiveness (AHR), suggesting a relationship between aspirin and methacholine in airway response. This study
was performed to determine whether methacholine AHR affects the response of asthmatics to inhaled aspirin.  
Methods: The clinical records of 207 asthmatic patients who underwent inhalation challenges with both aspirin
and methacholine were reviewed retrospectively. An oral aspirin challenge was performed in patients with a
negative inhalation response. The bronchial reactivity index (BRindex) was calculated from the percent decrease
in lung function divided by the last dose of the stimulus.  
Results: Forty-one (20.9%) and 14 (7.1%) patients showed a positive response to aspirin following an inhalation
and oral challenge, respectively. Only 24.3 and 14.3% of the responders had a history of aspirin intolerance,
respectively. The methacholine BRindex was significantly higher in the inhalation responders (1.46 ± 0.02) than
in the oral responders (1.36 ± 0.03, p < 0.01) and in non-responders (n = 141, 1.37 ± 0.01, p < 0.001). The aspirin
BRindex was significantly correlated with the methacholine BRindex (r = 0.270, p < 0.001). Three of four patients
who received the oral challenge, despite a positive inhalation test, showed negative responses to the oral
challenge. Two of these patients had severe AHR. 
Conclusions: A considerable number of asthmatic patients with no history of aspirin intolerance responded to
the inhalation aspirin challenge. The airway response to aspirin was significantly correlated with methacholine-
AHR, and a false-positive response to aspirin inhalation test seemed to occur primarily in patients with severe
AHR. (Korean J Intern Med 2010;25:309-316)
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INTRODUCTION
Asthmatic symptoms in approximately 14 to 29% of
adult asthmatics are exaggerated after the ingestion of
aspirin [1]. Aspirin-induced asthma (AIA) usually develops
as persistent rhinosinusitis with nasal polyposis, followed
by asthma and aspirin hypersensitivity [2]. The syndrome
is increasingly being referred to as aspirin-exacerbated
respiratory disease, as exposure to aspirin does not initiate
the disease, but does provoke strong asthmatic attacks in
the later stages of the disease.
Although a patient’s clinical history may give rise to
suspicion of AIA, the diagnosis can only be established
with certainty by aspirin provocation testing. A controlled
oral challenge with aspirin is regarded as the gold standard
for diagnosing AIA; however, the widely used three-day
challenge proposed by Manning and Stevenson [3] and
even the recently advocated two-day challenge protocol
[4] are time consuming and can produce severe asthmatic
reactions [5]. Consequently, an inhalation challenge with
lysine-aspirin is the preferred method.
The inhalation aspirin challenge was first introduced byBianco et al. [6] in 1977. It has since been demonstrated
that the inhalation challenge is less sensitive than oral
challenges, although it is safer and takes less time to
perform [2,7]. The oral challenge is regarded as positive
when severe extra-bronchial symptoms, such as nasal
blockade, appear even if the forced expiratory volume in 1
second (FEV1) does not decrease > 20% [4]. An inhalation
challenge rarely induces extra-bronchial symptoms. In
addition, it is reasonable to speculate that results from
an inhalation challenge are affected by the patient’s
underlying airway hyperresponsiveness (AHR). We have
found that irritable airways constrict easily even in
response to inhaled normal saline aerosols (unpublished
data), and the bronchial response to an inhaled allergen is
significantly related to methacholine AHR [8].
In previous sgudies [9-14] of 25 or fewer subjects, airway
responses to inhaled aspirin did not correlate with AHR.
Methacholine AHR was not significantly different
between 23 patients with AIA and 23 aspirin-tolerant
asthmatic subjects [10]. The degree of airway responsiveness
to lysine-aspirin was not related to histamine AHR in 11
[11] and 9 [12] AIA patients, or to methacholine AHR in 10
[13] and 25 AIA patients [14]. As AIA does not occur simply
as an epiphenomenon of severe asthma but develops in a
small subset of patients with asthma who have a genetic
predisposition [15], airway responsiveness to aspirin and to
methacholine or histamine are unlikely to be closely related.
Approximately half of the patients with AIA are oral
steroid-dependent, and thus, many of them have developed
severe AHR [16,17]. Therefore, AIA is related to AHR in a
broad sense, and a significant relationship could be
confirmed if studied using large numbers of subjects.
Moreover, inhalation rather than an oral challenge could
induce bronchospasms more easily in irritable airways. It
may also be possible for airways with severe AHR to
respond non-specifically to aspirin. Nonetheless, there are
no reports of a significant relationship between AIA and
AHR or of the irritant effects of aspirin in spasmodic
airways. Here, we report that airway responsiveness to




The clinical records of 207 asthmatic patients who
underwent both inhalation aspirin and methacholine
challenge testing at our hospital between 1997 and 2008
were reviewed retrospectively. Of these patients, 178
(86.0%) were adult men, 17 to 30 years old, seeking a
medical certificate for exemption from obligatory military
service. Thus, many of the subjects included in this study
had no previous history of an adverse reaction to aspirin
or other non-steroidal anti-inflammatory drugs. The
patients underwent several tests including an aspirin
challenge to diagnose asthma. The subjects were instructed
to refrain from using any medication for at least 7 days
before the tests. The study protocol was approved by the
Institutional Review Board of our hospital (IRB No. I-
2008-07-091).
Asthma was diagnosed if at least one of the following
criteria was fulfilled: the provocative concentration of
methacholine that resulted in a 20% fall in FEV1 (PC20)
was ≤ 16 mg/mL; histamine-PC20 ≤ 16 mg/mL; a
provocative dose of inhaled 4.5% hypertonic saline
resulting in a 15% fall in FEV1 < 20 mL; a maximal % fall
in FEV1 ≥ 15%  to an exercise test; or a change in FEV1 ≥
12% and ≥ 200 mL spontaneously or following treatment
for asthma. Increased numbers of blood eosinophils and
serum total IgE concentrations were defined as > 450
/mm3 [18] and > 100 IU/mL, respectively. A positive
serum level of house dust mite-specific IgE was defined
as > 3.5 kU/L (≥ 3+) measured using UniCAP®100ε
(Pharmacia Diagnostics, Uppsala, Sweden) for
Dermatophagoides farinae and/or Dermatophagoides
pteronyssinus. To diagnose aspirin intolerance, an aspirin
challenge was performed according to the method proposed
by Melillo et al. [13] with modifications. Briefly, the patients
underwent an inhalation aspirin challenge and, if the test
result was negative, received oral doses of 250 and 500 mg
of aspirin at 2-hour intervals to exclude aspirin sensitivity
not related to the inhalation challenge. The patients were
classified into three groups based on their inhalation and
oral aspirin challenge responses. Group I had a positive
response to the inhalation test, Group II had a positive
response to the oral challenge, and Group III had negative
responses to both tests. Eleven patients showed a negative
response to the inhalation test but did not receive the oral
challenge and were excluded from the classification. 
Airway responsiveness measurement 
A methacholine bronchoprovocation test was performed
on the first day, followed by administration of the aspirin
challenge on the second day. The methacholine test
followed a standardized tidal breathing protocol [19]. The
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duplicate at 30 and 90 s after each inhalation period using
a spirometer (SpiroAnalyzer ST-250, Fukuda Sangyo,
Tokyo, Japan). The highest FEV1 from the acceptable
spirograms was selected as the representative value for
each period [20]. The selected predictive equation for FEV1
was that recommended by the Intermountain Thoracic
Society [21]. Isotonic saline followed by methacholine
(Sigma-Aldrich, St. Louis, MO, USA) was aerosolized at
room temperature in a DeVilbiss 646 nebulizer (output
0.13 mL/min; DeVilbiss, Somerset, PA, USA). The
dilution increments were 0.075, 0.15, 0.31, 0.62, 1.25, 2.5,
5.0, 10, and 25 mg/mL. The aerosols were inhaled by tidal
breathing over 2 minutes at 5-minute intervals through
the mouth with the nose clipped. The challenge test was
discontinued if the FEV1 dropped by 20% or more from
the post-saline FEV1, or if the maximum concentration of
methacholine was administered. The PC20 was calculated
by linear interpolation of the log dose-response curve. The
severity of methacholine AHR was categorized by a
modification of the method of Woolcock and Jenkins [22]
as follows: severe, PC20 < 0.2; moderate, PC20 = 0.2 to 2.0;
mild, PC20 = 2.0 to 16.0; and normal, PC20 > 16 mg/mL.
As actual PC20 values could not be obtained for subjects
with a negative test response, the bronchial reactivity
index (BRindex) as an index of AHR was calculated as
follows: log10 (10 + maximal % fall in FEV1 / log10 [dose
in mg/dL of methacholine required to produce the
response]) [23].
An inhalation aspirin challenge was performed according
to the method of Phillips et al. [11]. Patients inhaled increasing
doses (11.25, 45, 180, and 360 mg/mL) of lysine-aspirin
(Ilyang, Seoul, Korea; 360 mg of lysine-aspirin is equivalent
to 200 mg of aspirin) after the saline challenge using a
dosimeter (Microdosimer, SM Instruments Co. Ltd.,
Doyles Town, PA, USA). The aerosols were inhaled ten times
from the end tidal volume to full inspiratory capacity at
30-minute intervals, and the FEV1 was measured at 10,
20, and 30 minutes after each inhalation period. The
lowest FEV1 of the three measurements was selected as
the representative value for each period [4]. The inhalation
challenge was discontinued if the FEV1 dropped by 20%
or more from the post-saline FEV1, or if the maximum
concentration of lysine-aspirin was administered. The
maximum cumulative dose of aspirin calculated according
to European guidelines [4] was 29.8 mg. A dose-response
curve was constructed, and the BRindex for aspirin was
calculated using an equation similar to that shown above
for methacholine. In subjects who ingested aspirin, the
FEV1 was measured 1 hour after ingestion and extra-
pulmonary symptoms were recorded. A positive response
to aspirin was defined as a decrease in FEV1 ≥ 20% from
the post-saline value or a fall in FEV1 ≥ 15% with extra-
pulmonary symptoms of intolerance such as rhinorrhea
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Table 1. Clinical characteristics of the asthmatic subjects classified according to their responses to the inhalation
and oral aspirin challenges
Characteristics Group Ia Group II b Group III c
(n = 41) (n = 14) (n = 141)
Male  36 (87.8) 13 (92.9) 127 (90.1)
Age, yr  23.8 ± 1.6 24.1 ± 3.5 23.2 ± 0.8
Height, cm  171.4 ± 1.1 171.3 ± 1.8 172.5 ± 0.6
Asthma duration, yr 6.5 ± 0.9 8.2 ± 1.5 6.5 ± 0.5
Aspirin intolerance historyd 9 (24.3) 2 (14.3) 10 (7.4)
Allergic rhinitis  27 (65.9) 7 (50.0) 88 (62.9)
Sinusitis  11 (28.2) 3 (23.1) 29 (20.9)
Blood eosinophils > 450 /mm3 14 (34.1) 5 (38.5) 32 (23.0)
Total IgE > 100 IU/mL  31 (79.5) 10 (76.9) 105 (78.9)
House dust mites-specific IgE ≥ 3+e 18 (66.7) 4 (44.4) 67 (65.7)
Values are presented as number (%) or mean ± SD.
An oral aspirin challenge was performed in cases of a negative response to the inhalation aspirin challenge.
aPositive response to inhalation aspirin challenge.
bPositive response to oral aspirin challenge.
cNegative response to both inhalation and oral aspirin challenges.
dp < 0.05 by χ2 analysis.
eThe levels of specific IgE for Dermatophagoides farinae and/or D. pteronyssinus were measured using the UniCAP®100ε system.and nasal congestion [24]. AIA was defined as a positive
response to the inhalation or oral aspirin challenge.
Statistical analysis
All data were analyzed by the Kruskal-Wallis test,
Mann-Whitney U test, χ2 test, Fisher’s exact test, or
Pearson’s correlation using SPSS version 17.0 (SPSS Inc.,
Chicago, IL, USA). All data are shown as the mean ±
standard error of the mean (SEM).  A p< 0.05 was considered
statistically significant.
RESULTS
Patient distribution and characteristics
The 196 asthmatic patients included in this study were
classified into three groups based on their inhalation and
oral aspirin challenge responses. Forty-one subjects
(20.9%) had a positive response to the inhalation test
(Group I), 14 subjects (7.1%) had a positive response to the
oral challenge (Group II), and 141 subjects (71.9%) had
negative responses to both tests (Group III). The remaining
11 patients, who were excluded from the classification,
showed a negative response to the inhalation test but did
not receive the oral challenge. Thus, a total of 55 (28.1%)
patients were diagnosed as AIA; the proportion of false
negative diagnosis following the inhalation challenge was
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Figure 1. The methacholine-PC20 (A) and BRindex (B) for patients with asthma classified according to their responses to the
inhalation and oral aspirin challenges. PC20, the provocative concentration of methacholine that resulted in a 20% decrease in the
forced expiratory volume in one second (FEV1); BRindex, the bronchial reactivity index calculated using the equation: log10 (10 +
maximal % fall in FEV1 / log10 [dose in mg/dL of methacholine required to produce the response]).
aPositive response to inhalation aspirin challenge.
bPositive response to oral aspirin challenge.
cNegative response to both inhalation and oral aspirin challenges.
Table 2. Prevalence of pulmonary or extra-pulmonary symptoms induced by the inhalation aspirin challenge in
asthmatic subjects classified according to their responses to the inhalation and oral aspirin challenges
Positive esponse Negative response χ2 p value
Inhalation 22/35 (62.9%) 26/142 (18.3%) 28.2 0.000
Oral 7/12 (58.3%) 19/120 (15.8%) 12.5 0.002
An oral aspirin challenge was performed in patients showing a negative response to the inhalation aspirin challenge.
A B25.5%. The clinical characteristics of the subjects are
summarized in Table 1. No differences in sex, age, height,
duration of asthma, associated allergic rhinitis and
sinusitis, blood eosinophilia, increased total IgE level, or
positivity for house dust mite-specific IgE were observed
among the groups. However, the prevalence rates of a
positive history of aspirin intolerance were significantly
different among the groups (24.3, 14.3, and 7.4% for
Groups I, II, and III, respectively; p< 0.05). In five (35.7%)
of the 14 patients in Group II, the oral challenge was
considered positive on the basis of extra-bronchial
symptoms even though the FEV1 decreased < 20% from
the post-saline value. When only the data of men aged ≤
30 years were analyzed, the results were similar to those
for the whole study population (subject distribution =
20.7, 7.1, and 72.2% for Groups I, II, and III, respectively).
Moreover, no difference in clinical characteristics was
noted among the groups except in the prevalence of a
history of aspirin intolerance (p < 0.01). Only three (9.7%)
of 31 patients in Group I had a positive history of aspirin
intolerance. 
Airway responsiveness to methacholine
Baseline FEV1 did not differ significantly among the
groups (mean values for Groups I-III: 84.5, 86.5, and
87.3%, respectively). However, the baseline FEV1 / forced
vital capacity (FVC) ratios were significantly lower in
Groups I (79.3 ± 1.5%) and II (78.3 ± 1.9%) than in Group
III (82.7 ± 0.8%; both p < 0.05). The log methacholine-
PC20 was significantly lower and the methacholine
BRindex was significantly higher in Group I (log PC20: -
0.24 ± 0.10; BRindex: 1.46 ± 0.02) than in Groups II (0.12
± 0.16, p < 0.05; 1.36 ± 0.03, p < 0.01) and III (0.23 ±
0.07, p < 0.001; 1.37 ± 0.01, p < 0.001), respectively (Fig.
1). However, neither methacholine measurement was
significantly different between Groups II and III. The
distribution of the severity of methacholine AHR differed
significantly among the groups (Fig. 2). The proportion of
subjects with severe methacholine AHR to total patients
was significantly higher in Group I than in the others
(11/41 [26.8%] vs. 21/166 [12.7%], p < 0.05). However, it
was not significantly different between the subjects with
and without AIA (13/55 [23.6%] vs. 18/141 [12.8%], p =
0.061). In addition, both the methacholine-PC20 and
BRindex were significantly correlated with the aspirin
BRindex (Fig. 3). 
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Figure 2. Distribution of the severity of methacholine airway
hyperresponsiveness (AHR) in patients with asthma, classified
according to their responses to the inhalation and oral aspirin
challenges. The values of the provocative concentration of
methacholine that resulted in a 20% decrease in the forced
expiratory volume in one second (PC20) were divided as follows:
severe, PC20 < 0.2; moderate, PC20 = 0.2 to 2.0; mild, PC20 =
2.0 to 16; and normal, PC20 > 16 mg/mL.
aPositive response to inhalation aspirin challenge.
bPositive response to oral aspirin challenge.
cNegative response to both inhalation and oral aspirin challenges.
Figure 3. Relationship of airway responsiveness between the
aspirin and methacholine bronchial reactivity index (BRindex),
calculated using the equation: log10 (10 + maximal % fall in
FEV1 / log10 [dose in mg/dL of stimulus required to produce the
response]). Inhalation-aspirin-challenge-induced symptoms
The prevalence of pulmonary or extra-pulmonary
symptoms that occurred in response to the inhalation
aspirin challenge in patients with a positive response to
the inhalation challenge (Group I) was significantly higher
than in the others (Table 2). In addition, inhaled-aspirin-
induced symptoms occurred more frequently in Group II
than in Group III. However, seven patients symptomatic
for inhalation, as well as the whole study population in
Group II, showed no significant differences in methacholine
responsiveness from Group III. In Group I, the FEV1 / FVC
ratios in the patients who were symptomatic following the
inhalation aspirin challenge were significantly lower than
in those who were not (77.4 ± 1.5 vs. 83.6 ± 3.5%, p< 0.01).
However, among patients with a negative response to the
inhalation challenge, the symptomatic subjects showed no
significant difference in clinical characteristics from the
others.
Four patients received an oral challenge despite having
a positive response to the inhalation challenge due to
the absence of associated symptoms. Only one of these
subjects showed a positive response to the oral challenge,
suggesting false-positive responses to the inhalation
challenge in many patients. The methacholine-PC20 was
0.74 mg/mL in a patient showing a positive oral challenge
result compared with 0.09 and 0.12 mg/mL in two patients
with a negative result. The remaining patient who showed
a positive result on inhalation challenge but a negative
result on oral challenge had a methacholine-PC20 > 25
mg/mL; however, even though his FEV1 30 minutes after
the inhalation of 360 mg/mL aspirin decreased by 24.7%
from the post-saline value, the FEV1 at 10 minutes
decreased by only 16.2%, which was below the cutoff value
(20%) for a positive response.
DISCUSSION
A relationship between AHR and aspirin can be inferred
based on the fact that many patients with AIA are oral
steroid dependent [16,17] and thus have severe AHR. This
is the first study to definitively demonstrate a significant
relationship between methacholine AHR and airway
responses to an inhalation aspirin challenge. In this study,
the methacholine-PC20 was significantly lower, whereas
the methacholine-BRindex was significantly higher, in
subjects with a positive response to the inhalation aspirin
challenge than in the other groups. Moreover, airway
responsiveness to methacholine was significantly
correlated with that to aspirin. Our results also support a
role for severe AHR in AIA by showing that a higher
proportion of subjects with a positive inhalation challenge
result had severe AHR compared to the proportions in the
other groups. In previous studies [9-14], a relationship
between AHR and AIA was not seen, suggesting that the
number of subjects in these studies may have been too
small (≤ 25) for the results to reach statistical significance.
Considering the natural history of AIA [17], patients
with full-blown AIA who respond to the inhalation
challenge may have had relatively severe AHR, whereas
those with AIA who respond only to oral challenge may
have had less severe AHR, similar to that of non-AIA
patients. The responsiveness to methacholine in those
subjects with a positive inhalation challenge result (Group
I) was significantly different from that in those who
showed a positive response to the oral challenge only
(Group II), and no difference was found between Groups
II and III even though the FEV1 / FVC ratio was signifi-
cantly lower in Group II than in Group III. Thus, the
prevalence of severe AHR was significantly higher in the
AIA group than in the other groups when the inhalation
challenge alone was used for the diagnosis of AIA, but not
when the oral challenge was included. Nizankowska et al.
[7] suggested that most patients with a positive response
to oral challenge alone were considered positive on the
basis of extra-bronchial symptoms. However, only 35.7%
of the subjects in Group II were considered to show a
positive oral challenge result on the basis of extra-
bronchial symptoms in the present study. Taken together,
these observations suggest that patients with AIA who
responded to the oral challenge alone may have had less
severe AHR.
Although a significant relationship between methacholine
AHR and the airway response to an inhalation aspirin
challenge was found in this study, additional studies are
required to determine whether aspirin intolerance is the
cause of methacholine AHR or whether methacholine
AHR results in a positive response to an inhalation aspirin
challenge. As irritable airways constrict easily in response
to various inhaled stimuli, the inhalation rather than
ingestion of aspirin may affect airway responsiveness
to the challenge. Therefore, to confirm the relationship
between airway responsiveness to methacholine and to
aspirin, it is necessary to use an oral aspirin challenge,
even though almost all patients with positive inhalation
responses also respond positively to the oral challenge
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AHR is altered with time may be necessary to determine
the extent to which AHR non-specifically affects
inhalation aspirin challenge results, despite the
repeatability of the inhalation aspirin challenge reported
by Phillips et al. [11]. However, such efforts may not yield
meaningful results because the underlying aspirin
intolerance determined by an oral challenge can disappear
with improvements in methacholine AHR due to asthma
therapy [25].
Irritable airways may respond to inhaled aspirin non-
specifically in asthma patients without aspirin intolerance.
Our data supports this hypothesis because we found that
three of four patients who received an oral challenge,
despite having a positive response to the inhalation challenge
due to the absence of associated symptoms, showed a
negative response to the oral challenge. Furthermore, two
negative oral responders had severe AHR. In another
negative oral responder, FEV1 decreased in only one of the
three measurements after the inhalation of 360 mg/mL
aspirin to fulfill the positive criteria in which the lowest
value was used as the representative result [4]. Therefore,
it is possible that false-positive responses to aspirin
occurred when the inhalation challenge was performed in
patients with severe AHR who were asymptomatic to the
inhalation challenge, or when the FEV1 decreased only
transiently after the challenge. The high dose of inhaled
aspirin used here does not pose a problem, as it is
comparable to that reported by Phillips et al. [11], and
recent guidelines [4] recommend as many as 43 breaths of
2 M (720 mg/mL) lysine-aspirin.
The rate of false-negative responses to the inhalation
aspirin challenge was 25.5% in the present study. The
maximum cumulative dose of aspirin (29.8 mg) used in
this study may have resulted in false-negative results
because it was only 16.4% of the 181.98 mg recommended
by European guidelines [4] and used by Nizankowska et
al. [7]. However, the sensitivity of the inhalation challenge
reported by Nizankowska et al. [7] was only 77%, despite
that strong extra-bronchial symptoms were added to a fall
in FEV1 > 20% as indicating a positive response.
Therefore, an additional oral challenge is desirable in
cases in which the highest inhaled aspirin concentration
fails to induce bronchospasms. The false-negative
responders to the inhalation aspirin challenge complained
of bronchial or extra-bronchial symptoms more frequently
in this study. Thus, an oral challenge should be added for
patients symptomatic to an inhalation challenge.
The AIA prevalence rate in the present study (28.1%) is
consistent with that reported previously (14 to 29%) [1].
The factors mentioned above (i.e., underlying AHR,
challenge method, positivity criteria, etc.) affect the
prevalence of AIA. In addition, many patients with AIA
are oral steroid dependent [16,17]; thus, an inhalation
challenge cannot be performed due to airway instability
[7]. Szczeklik et al. [17] reported that 15% of patients with
AIA were unaware of their intolerance to aspirin and
learned about it only after undergoing provocation testing.
In the present study, 90.3% of the young adult male
patients who required a medical certificate for exemption
from obligatory military service had no previous history of
aspirin intolerance. The most important reason for this
discrepancy is that we examined aspirin intolerance
routinely in these patients for the purpose of providing the
necessary certificates.
In the present study, a considerable number of asthmatic
subjects without a positive history of aspirin intolerance
responded to the inhalation aspirin challenge. The
airway response to aspirin was significantly related to
methacholine AHR, and a false-positive response to the
inhalation challenge would be expected in patients with
severe AHR. 
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